Determinants of response to bevacizumab in colon cancer

结肠癌贝伐单抗反应的决定因素

• 批准号: 6858004
• 负责人: Peter J ODwyer
• 金额: $ 13.63万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-07-06 至 2007-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6858004
• 关键词: DNA repair; angiogenesis; angiogenesis inhibitors; apoptosis; biomarker; biotechnology; clinical research; colorectal neoplasms; combination chemotherapy; drug metabolism; enzyme activity; fluorouracil; genotype; human tissue; immunofluorescence technique; migration inhibition factor; mitogen activated protein kinase; monoclonal antibody; neoplasm /cancer blood supply; neoplasm /cancer immunotherapy; neoplasm /cancer pharmacology; pharmacogenetics; single nucleotide polymorphism; vascular endothelial growth factors

DESCRIPTION (provided by applicant): This proposal investigates the relationship between markers of angiogenesis in colorectal tumors and treatment outcome with a regimen containing bevacizumab, an anti-VEGF antibody. The proposal also explores the determinants of the biology of angiogenesis, the effects of its inhibition on tumor cell survival, and the sources of interpatient pharmacogenetic variability that may underlie treatment effects with 5-fluorouracil, oxaliplatin and bevacizumab. To accomplish these objectives, the proposal utilizes tumor blocks collected through the Eastern Cooperative Oncology Group (ECOG) Trial E3200, a randomized study of 5-fluorouracil, Oxaliplatin With or Without Bevacizumab.

描述（由申请人提供）：该提案研究了结直肠肿瘤中血管生成标志物与含有贝伐单抗（一种抗 VEGF 抗体）的治疗结果之间的关系。该提案还探讨了血管生成生物学的决定因素、其抑制对肿瘤细胞存活的影响，以及患者间药物遗传学变异的来源，这些变异可能是 5-氟尿嘧啶、奥沙利铂和贝伐珠单抗治疗效果的基础。为了实现这些目标，该提案利用了通过东部肿瘤合作组 (ECOG) 试验 E3200 收集的肿瘤块，这是一项针对 5-氟尿嘧啶、奥沙利铂联合或不联合贝伐珠单抗的随机研究。